Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    master dapt
Previous Study | Return to List | Next Study

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen (MASTER DAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03023020
Recruitment Status : Active, not recruiting
First Posted : January 18, 2017
Last Update Posted : December 24, 2019
Sponsor:
Collaborators:
Cardialysis B.V.
European Cardiovascular Research Center
University of Bern
Terumo Medical Corporation
Information provided by (Responsible Party):
ECRI bv

Tracking Information
First Submitted Date  ICMJE December 29, 2016
First Posted Date  ICMJE January 18, 2017
Last Update Posted Date December 24, 2019
Actual Study Start Date  ICMJE April 4, 2017
Estimated Primary Completion Date November 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 13, 2017)
  • Net adverse clinical endpoints (NACE) defined as a composite of all-cause death, myocardial infarction, stroke and bleeding events defined as BARC 3 or 5 [ Time Frame: 11 months ]
  • Major adverse cardiac and cerebral events (MACCE) defined as a composite of all-cause death, myocardial infarction and stroke [ Time Frame: 11 months ]
  • Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events [ Time Frame: 11 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 13, 2017)
  • All cause death [ Time Frame: 14 months ]
  • Death from cardiovascular causes [ Time Frame: 14 months ]
  • Myocardial infarction [ Time Frame: 14 months ]
  • Stroke [ Time Frame: 14 months ]
  • Bleeding events [ Time Frame: 14 months ]
  • Definite or probable stent thrombosis [ Time Frame: 14 months ]
  • Any target vessel revascularization [ Time Frame: 14 months ]
  • Urgent target vessel revascularization [ Time Frame: 14 months ]
  • Urgent non-target vessel revascularization [ Time Frame: 14 months ]
  • Clinically indicated non-target vessel revascularization [ Time Frame: 14 months ]
  • Transfusion rates both in patients with and/or without clinically detected over bleeding [ Time Frame: 14 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
Official Title  ICMJE Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
Brief Summary

The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with a drug covered stent (metallic tube).

This comparison will be done in patients who, compared to the average patient, are more likely to suffer from complications on antiplatelet therapy (bleeding). Both durations are within the current medical recommendations. The aim of this study is to help improve further standard antiplatelet duration guidelines.

Detailed Description

The study objective is to determine in a high bleeding risk patient population undergoing PCI under standardized treatment (within current guidelines and instructions for use and including the bioresorbable polymer coated Ultimaster sirolimus-eluting stent), whether abbreviated DAPT is non-inferior to prolonged DAPT regimen in terms of NACE within 12 months, whether abbreviated DAPT is non-inferior to prolonged DAPT regimen in terms of MACCE within 12 months and whether abbreviated DAPT is superior to prolonged DAPT regimen in terms of MCB within 12 months.

There are two treatment strategies:

  • abbreviated dual anti-platelet therapy: dual antiplatelet therapy is discontinued and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation). In patients on oral anticoagulants, dual antiplatelet therapy is discontinued and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation) OR
  • prolonged dual anti-platelet therapy: aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation). In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Therefore either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)

The study design is an investigator-initiated, randomized, multi-center, clinical trial to be conducted in approximately 100 interventional cardiology centers in across the globe excluding USA. The study includes 2 x 2150 patients (i.e. 4300 patients) Randomization will occur at one month after the PCI procedure. The expected duration of participation for each patient is 14 months.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • High Bleeding Risk
  • Coronary Artery Disease
  • PCI
Intervention  ICMJE
  • Drug: Aspirin
    Dosing per current guidelines and local practice
    Other Name: antiplatelet agent
  • Drug: P2Y12 inhibitor
    Dosing per current guidelines and local practice
    Other Name: antiplatelet agent
Study Arms  ICMJE
  • Abbreviated antiplatelet regimen

    Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).

    In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)

    Interventions:
    • Drug: Aspirin
    • Drug: P2Y12 inhibitor
  • Prolonged antiplatelet regimen

    Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).

    In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)

    Interventions:
    • Drug: Aspirin
    • Drug: P2Y12 inhibitor
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: January 13, 2017)
4300
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2021
Estimated Primary Completion Date November 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

After index PCI, patients aged 18 years or more are eligible for inclusion into the study if the following criteria are met.

  1. At least one among the HBR criteria (as defined below) is met.
  2. All lesions are successfully treated with Ultimaster stent in the context of routine clinical care, i.e. post-procedural angiographic diameter stenosis <20% by visual estimation
  3. Free from any flow-limiting angiographic complications (i.e. significant untreated dissection or major side-branch occlusion), which require prolonged DAPT duration based on operator's opinion.
  4. All stages of PCI are complete (if any) and no further PCI is planned.

At randomization visit (one month after index PCI), the following criteria must be met:

  1. Fulfilment of at least one HBR criterion (as defined below), or on the basis of post-PCI actionable (i.e. requiring medical attention) non-access site related bleeding episode
  2. Uneventful 30-day clinical course, i.e. free from spontaneous MI, symptomatic restenosis, stent thrombosis, stroke and any revascularization (coronary and non-coronary) requiring prolonged DAPT
  3. If not on OAC,

    1. Patient is on a DAPT regimen of aspirin and a P2Y12 inhibitor
    2. Patient with one type of P2Y12 inhibitor for at least 7 days (i.e. no switching between oral P2Y12 inhibitors has occurred in the previous 7 days)
  4. If on OAC

    1. Patient is on the same type of OAC (e.g. Vitamin K antagonist or NOAC) for at least 7 days
    2. Patient is on clopidogrel for at least 7 days

Definition of HBR

Post-PCI patients are at HBR if at least one of the following criteria applies:

  • Clinical indication for treatment with oral anticoagulants (OAC) for at least 12 months
  • Recent (<12 months) non-access site bleeding episode(s), which required medical attention (i.e. actionable bleeding).
  • Previous bleeding episode(s) which required hospitalization if the underlying cause has not been definitively treated (i.e. surgical removal of the bleeding source)
  • Age equal or greater than 75 years
  • Systemic conditions associated with an increased bleeding risk (e.g. haematological disorders, including a history of or current thrombocytopaenia defined as a platelet count <100,000/mm3 (<100 x 109/L), or any known coagulation disorder associated with increased bleeding risk.
  • Documented anaemia defined as repeated haemoglobin levels <11 g/dl or transfusion within 4 weeks before randomization.
  • Need for chronic treatment with steroids or non-steroidal anti-inflammatory drugs
  • Diagnosed malignancy (other than skin) considered at high bleeding risk including gastro-intestinal, genito-urethral/renal and pulmonary.
  • Stroke at any time or TIA in the previous 6 months
  • PRECISE DAPT score of 25 or greater

Exclusion Criteria:

  1. Treated with stents other than Ultimaster stent within 6 months prior to index procedure
  2. Treated for in-stent restenosis or stent thrombosis at index PCI or within 6 months before
  3. Treated with a bioresorbable scaffold at any time prior to index procedure
  4. Cannot provide written informed consent
  5. Under judicial protection, tutorship or curatorship
  6. Unable to understand and follow study-related instructions or unable to comply with study protocol
  7. Active bleeding requiring medical attention (BARC≥2) on randomization visit
  8. Life expectancy less than one year
  9. Known hypersensitivity or allergy for aspirin, clopidogrel, ticagrelor, prasugrel, cobalt chromium or sirolimus
  10. Any planned and anticipated PCI
  11. Participation in another trial
  12. Pregnant or breast feeding women
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Bahrain,   Bangladesh,   Belgium,   Bulgaria,   Czechia,   Denmark,   Estonia,   France,   Germany,   Hungary,   India,   Israel,   Italy,   Japan,   Korea, Republic of,   Netherlands,   North Macedonia,   Poland,   Saudi Arabia,   Serbia,   Singapore,   Slovenia,   Spain,   Sweden,   Switzerland,   United Kingdom,   Vietnam
Removed Location Countries Macedonia, The Former Yugoslav Republic of
 
Administrative Information
NCT Number  ICMJE NCT03023020
Other Study ID Numbers  ICMJE ECRI-009
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party ECRI bv
Study Sponsor  ICMJE ECRI bv
Collaborators  ICMJE
  • Cardialysis B.V.
  • European Cardiovascular Research Center
  • University of Bern
  • Terumo Medical Corporation
Investigators  ICMJE
Principal Investigator: M. Valgimigli, Prof. Inselspital Universitätsspital Bern, Switzerland
Principal Investigator: P. Smits, Dr. Maasstad Ziekenhuis Rotterdam, The Netherlands
Study Director: R Van Amsterdam ECRI bv
PRS Account ECRI bv
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP